Eisai Inc. (pronounced ā-zī) is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd, a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business. Headquartered in Woodcliff Lake, New Jersey, we are dedicated to a tradition of genuine concern for people and are driven by the desire to help meet the diverse health care needs of patients and their families and caregivers. We are an agile, entrepreneurial organization managed by experienced leadership, backed by the strength, stability and historical successes of Eisai Co., Ltd., which has a strong and lasting commitment to the U.S. market. Our heritage and mission have earned us recognition as an innovative, efficient, solution-oriented pharmaceutical company - a company that effectively works with healthcare professionals, hospitals and managed care organizations to develop and market specialty products that help address unmet needs. Our ability to forge strong alliances gives us a competitive edge. In the United States, our rapid growth and strong performance result from putting patients and their families first when making decisions and from empowering the people who manage our operations. Eisai employees personify our values of integrity, respect, professionalism, quality and teamwork. As you continue exploring our corporate web site, you will learn more about how our commitment to hhc is a motivating force for everything we do and everything we produce..
Woodcliff Lake, US
Size (employees)
10,495 (est)
Eisai was founded in 1941 and is headquartered in Woodcliff Lake, US

Eisai Office Locations

Eisai has an office in Woodcliff Lake
Woodcliff Lake, US (HQ)
100 Tice Blvd

Eisai Financials and Metrics

Eisai Financials


Market capitalization (31-Oct-2017)

15.9 b

Closing share price (31-Oct-2017)

Eisai's current market capitalization is $15.9 b.
Show all financial metrics

Eisai Market Value History

Eisai Median Salaries

Source: 36 public H-1B filings from Eisai

Eisai's Web-traffic and Trends

Eisai Online and Social Media Presence

Eisai News and Updates

Eisai's Lenvima nabs survival edge in liver cancer showdown with Bayer's Nexavar

Bayer and its stalwart Nexavar have had the first-line liver cancer field to themselves for years. But Eisai is doing its best to change that.

Eisai Company Life and Culture

You may also be interested in